Primary study · included by 1 review
Response to Treatment with Melatonin and Clonazepam versus Placebo in Patients with Burning Mouth Syndrome
Castillo-Felipe 2022 · Castillo-Felipe Candela, Tvarijonaviciute Asta, López-Arjona Marina, et al. · Journal of Clinical Medicine · 2022
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (>4 to 12 weeks) | SMD -0.29 [-1.31, 0.73] | 3 studies · 144 participants | Very low |
Pain intensity Pharmacological agents and supplements vs Inactive control (placebo, sham, usual care or no intervention) · Short-term (immediate to 4 weeks) | SMD -0.40 [-7.46, 6.66] | 2 studies · 126 participants | GRADE not reported |
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (>4 to 12 weeks) | SMD -0.60 [-1.71, 0.52] | NR | GRADE not reported |
Pain intensity Pharmacological agents and supplements vs Inactive control (placebo, sham, usual care or no intervention) · Short-term (immediate to 4 weeks) | SMD -0.50 [-0.90, -0.11] | 2 studies · 126 participants | GRADE not reported |
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Short-term (immediate post-intervention to 4 weeks) | SMD -0.40 [-7.46, 6.66] | 2 studies · 126 participants | Very low |
Pain intensity Pharmacological agents and supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (more than 4 to 12 weeks) | SMD -0.26 [-0.63, 0.11] | 3 studies · 144 participants | GRADE not reported |
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (>4 to 12 weeks) | SMD -0.60 [-1.71, 0.52] | 2 studies | GRADE not reported |
Pain intensity Pharmacological agents and supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (more than 4 to 12 weeks) | SMD -0.29 [-1.31, 0.73] | 3 studies · 144 participants | GRADE not reported |
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (>4 to 12 weeks) | SMD -0.38 [-2.22, 1.46] | 2 studies | GRADE not reported |
Pain intensity Pharmacological agents or supplements vs Inactive control (placebo, sham, usual care or no intervention) · Mid-term (>4 to 12 weeks) | SMD 0.29 [-2.43, 3.01] | 2 studies | GRADE not reported |
1 including review in total.